GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galmed Pharmaceuticals Ltd (FRA:GPH) » Definitions » 5-Year EBITDA Growth Rate

Galmed Pharmaceuticals (FRA:GPH) 5-Year EBITDA Growth Rate : 49.10% (As of Dec. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Galmed Pharmaceuticals 5-Year EBITDA Growth Rate?

Galmed Pharmaceuticals's EBITDA per Share for the three months ended in Dec. 2024 was €-0.94.

During the past 3 years, the average EBITDA Per Share Growth Rate was 69.70% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 49.10% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 19.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Galmed Pharmaceuticals was 69.70% per year. The lowest was -32.80% per year. And the median was 4.00% per year.


Competitive Comparison of Galmed Pharmaceuticals's 5-Year EBITDA Growth Rate

For the Biotechnology subindustry, Galmed Pharmaceuticals's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Galmed Pharmaceuticals's 5-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Galmed Pharmaceuticals's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Galmed Pharmaceuticals's 5-Year EBITDA Growth Rate falls into.


;
;

Galmed Pharmaceuticals 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.


Galmed Pharmaceuticals  (FRA:GPH) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.


Galmed Pharmaceuticals 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Galmed Pharmaceuticals's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Galmed Pharmaceuticals Business Description

Traded in Other Exchanges
Address
16 Abba Hillel Road, Ramat Gan, ISR, 5250608
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.

Galmed Pharmaceuticals Headlines

No Headlines